Merck KGaA Ties Up Chord To Advance Cladribine Rare Disease Programs
Acquires Swiss Biotech To Expand Neurology Pipeline
Executive Summary
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
You may also be interested in...
Merck KGaA Health Care Head Happy With Old And New Mix
The German firm’s pharma chief Peter Guenter says that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.
Merck KGaA Healthcare Head Happy With Old And New Mix
The German firm’s pharma chief Peter Guenter tells Scrip that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.
Merck KGaA Keeps Powder Dry On Licensing Deals
After doing a number of healthcare deals in 2021, it looks as though Merck KGaA will keep M&A activity to a minimum for the division this year, focusing instead on advancing its own promising candidates for cancer, multiple sclerosis and lupus.